SCP
BNTX icon

Stamos Capital Partners’s BioNTech BNTX Stock Holding History

Stamos Capital Partners’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,870
Closed -$428K – 186
2022
Q2 		$428K Hold
2,870
– – 0.13% 91
2022
Q1 		$490K Buy
+2,870
New +$482K 0.16% 79

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Stamos Capital Partners's BNTX Position: Q3 2022 in Review

Stamos Capital Partners sold out of BioNTech (BNTX) in Q3 2022, closing a stake of 2,870 shares — an estimated $428K sold.

Stamos Capital Partners first reported a position in BNTX in Q1 2022 and held it in 2 quarters. The position peaked at $490K in Q1 2022. 264 funds tracked by Wall St. Rank hold BNTX as of Q3 2022.

  • Stamos Capital Partners reported no remaining BioNTech position as of Q3 2022 after selling out during the quarter.
  • Stamos Capital Partners sold 2,870 BioNTech shares in Q3 2022, an estimated $428K.
  • Stamos Capital Partners first reported a position in BioNTech in Q1 2022 and held it in 2 quarters.
  • Stamos Capital Partners's BioNTech position peaked at $490K in Q1 2022.
  • 264 funds tracked by Wall St. Rank held BioNTech as of Q3 2022.

Based on Stamos Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.